Dallas neurology and associate professor Dr. Michael W. Connolly and associate neurologist Dr. Eric H. Dickey are presenting their latest research in the latest edition of the “Eur Neurosciences” podcast.
In the latest episode of “EurekAlerts,” Dickey and Connolly talk about the impact of opioid medications on the brain.
Dickey said the opioid epidemic is a problem that will likely require more resources in the coming years than it has in the past.
“When you start to look at what we’re talking about, opioids are a big problem,” he said.
“We have this opioid epidemic that is being felt in a wide variety of health systems across the country.
There is a lot of evidence that opioids are associated with many health outcomes.
And so there is a significant need to have a robust research program in this area.”
And we’re trying to fill that gap.
And it’s a really exciting time to be a neurologist because we’re seeing a lot more treatments that are designed to treat neurodegenerative disorders.
“This is a very, very big epidemic, and it’s going to take a lot, and a lot is being spent on it,” he added.
The Dickey-Connolly research is published in the current issue of “Neuropsychopharmacology” by the American Academy of Neurology.
In addition to Dickey, co-authors are Associate Professor John A. Pang, MD, and Associate Professor David H. DeYoung, MD.
They are also authors on several other papers that were published this year.
They have been working to address the impact that opioid use has on the human brain for the last 15 years.
Dr. Connelly, who is also a professor of neurology at the University of Southern California and director of the Neuro-oncology Institute at the Walter Reed National Military Medical Center, said he and his team are particularly interested in how opioids and their opioid antagonists work to affect neurodegenesis and other brain conditions.
“We are focusing on the opioid system,” he told Eur Neuroscience.
What we are looking at here is a pathway that is involved in regulating a wide range of functions in the human neural system, including brain function, learning and memory, cognition, and the way that the brain processes information,” he explained. “
Our research has been examining how opioids can cause neurodegensic changes in the brainstem, and we have found that this affects the activity of a key pathway in the neuronal circuits.”
“What we’re finding is that it also has an impact on brain function in a way that has profound implications for people who are at high risk of developing neurodegeners.””
One of the key pathways that the researchers have been studying is the opioid receptor, or NR2B. “
What we’re finding is that it also has an impact on brain function in a way that has profound implications for people who are at high risk of developing neurodegeners.”
One of the key pathways that the researchers have been studying is the opioid receptor, or NR2B.
It is a gene, which has been shown to regulate a range, including how a substance behaves.
“In the human CNS, NR2A is a key component in the neurotransmitter system, and NR2 is a critical regulator of neurotransmitters and neurotransmitter receptors in the nervous system,” said Dr. Connellys co-author.
“NR2A has been implicated in the regulation of mood, emotion, sleep and anxiety, and in some cases, the regulation or control of a wide array of neurodegendensic processes.”
In a study conducted in 2013, the researchers discovered that the opioid antagonist, rimonabant, could affect the activity and activity of the NR2 receptor.
“It has the potential to impact the NR3B receptor, which was previously thought to be involved in neurodegening,” Dr. Dettwyler said.
“So this is a first step in identifying how opioids could affect brain function and function of NR2 receptors.”
The researchers have also been investigating whether opioids also impact NR2C receptors, which are involved in the neurodegender and neuroprotection pathways, and also in other neurodegentities.
“These receptors are involved with a number of neuroprotective pathways in the CNS, including the regulation and control of calcium homeostasis and other processes,” Dr Dettwys said.
Dr Detttyl said the research in these two areas are in their early stages.
“There are a number, many studies in the literature that are looking to find more evidence about the effects of opioids on these pathways,” he noted.
“There’s also a lot that is still in the works, and there are many questions that we don’t know enough about.”